Figure 2.

The phenotype of PGC/MUC1/MUC2 co-expression in the same pathological changes (× 200). A. The negative expression of PGC in moderately differentiated adenocarcinoma (MDA) group. B. The positive expression of MUC1 in MDA group. C. The positive expression of MUC2 in MDA group. D. The negative expression of PGC in poorly differentiated adenocarcinoma (PDA) group. E. The positive expression of MUC1 in PDA group. F. The negative expression of MUC2 in PDA group. G. The negative expression of PGC in signet ring cell carcinoma (SRCC) group. H. The negative expression of MUC1 in SRCC group. I. The positive expression of MUC2 in SRCC group. Every three figures in a horizontal composition were all from the same individual. The arrow all means the cells of pathological changes.

Xu et al. BMC Clinical Pathology 2013 13:21   doi:10.1186/1472-6890-13-21
Download authors' original image